Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
15,843
archived clinical trials in
Colorectal Cancer

A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy
A Phase 2, Open Label, Multicenter, Randomized Trial Comparing Tivozanib in Combination With mFOLFOX6 to Bevacizumab in Combination With mFOLFOX6, In Stage IV Metastatic Colorectal Cancer (mCRC) Subjects
Status: Enrolling
Updated:  2/19/2013
Kaiser Foundation Hospitals
mi
from
Honolulu, HI
A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy
A Phase 2, Open Label, Multicenter, Randomized Trial Comparing Tivozanib in Combination With mFOLFOX6 to Bevacizumab in Combination With mFOLFOX6, In Stage IV Metastatic Colorectal Cancer (mCRC) Subjects
Status: Enrolling
Updated: 2/19/2013
Kaiser Foundation Hospitals
mi
from
Honolulu, HI
Click here to add this to my saved trials
A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy
A Phase 2, Open Label, Multicenter, Randomized Trial Comparing Tivozanib in Combination With mFOLFOX6 to Bevacizumab in Combination With mFOLFOX6, In Stage IV Metastatic Colorectal Cancer (mCRC) Subjects
Status: Enrolling
Updated:  2/19/2013
University of Hawaii
mi
from
Honolulu, HI
A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy
A Phase 2, Open Label, Multicenter, Randomized Trial Comparing Tivozanib in Combination With mFOLFOX6 to Bevacizumab in Combination With mFOLFOX6, In Stage IV Metastatic Colorectal Cancer (mCRC) Subjects
Status: Enrolling
Updated: 2/19/2013
University of Hawaii
mi
from
Honolulu, HI
Click here to add this to my saved trials
A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy
A Phase 2, Open Label, Multicenter, Randomized Trial Comparing Tivozanib in Combination With mFOLFOX6 to Bevacizumab in Combination With mFOLFOX6, In Stage IV Metastatic Colorectal Cancer (mCRC) Subjects
Status: Enrolling
Updated:  2/19/2013
Queen's Medical Center
mi
from
Honolulu, HI
A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy
A Phase 2, Open Label, Multicenter, Randomized Trial Comparing Tivozanib in Combination With mFOLFOX6 to Bevacizumab in Combination With mFOLFOX6, In Stage IV Metastatic Colorectal Cancer (mCRC) Subjects
Status: Enrolling
Updated: 2/19/2013
Queen's Medical Center
mi
from
Honolulu, HI
Click here to add this to my saved trials
A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy
A Phase 2, Open Label, Multicenter, Randomized Trial Comparing Tivozanib in Combination With mFOLFOX6 to Bevacizumab in Combination With mFOLFOX6, In Stage IV Metastatic Colorectal Cancer (mCRC) Subjects
Status: Enrolling
Updated:  2/19/2013
Northwestern University
mi
from
Chicago, IL
A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy
A Phase 2, Open Label, Multicenter, Randomized Trial Comparing Tivozanib in Combination With mFOLFOX6 to Bevacizumab in Combination With mFOLFOX6, In Stage IV Metastatic Colorectal Cancer (mCRC) Subjects
Status: Enrolling
Updated: 2/19/2013
Northwestern University
mi
from
Chicago, IL
Click here to add this to my saved trials
A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy
A Phase 2, Open Label, Multicenter, Randomized Trial Comparing Tivozanib in Combination With mFOLFOX6 to Bevacizumab in Combination With mFOLFOX6, In Stage IV Metastatic Colorectal Cancer (mCRC) Subjects
Status: Enrolling
Updated:  2/19/2013
Illinios Cancer Care
mi
from
Peoria, IL
A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy
A Phase 2, Open Label, Multicenter, Randomized Trial Comparing Tivozanib in Combination With mFOLFOX6 to Bevacizumab in Combination With mFOLFOX6, In Stage IV Metastatic Colorectal Cancer (mCRC) Subjects
Status: Enrolling
Updated: 2/19/2013
Illinios Cancer Care
mi
from
Peoria, IL
Click here to add this to my saved trials
A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy
A Phase 2, Open Label, Multicenter, Randomized Trial Comparing Tivozanib in Combination With mFOLFOX6 to Bevacizumab in Combination With mFOLFOX6, In Stage IV Metastatic Colorectal Cancer (mCRC) Subjects
Status: Enrolling
Updated:  2/19/2013
Edward Kaplan and Associates
mi
from
Skokie, IL
A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy
A Phase 2, Open Label, Multicenter, Randomized Trial Comparing Tivozanib in Combination With mFOLFOX6 to Bevacizumab in Combination With mFOLFOX6, In Stage IV Metastatic Colorectal Cancer (mCRC) Subjects
Status: Enrolling
Updated: 2/19/2013
Edward Kaplan and Associates
mi
from
Skokie, IL
Click here to add this to my saved trials
A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy
A Phase 2, Open Label, Multicenter, Randomized Trial Comparing Tivozanib in Combination With mFOLFOX6 to Bevacizumab in Combination With mFOLFOX6, In Stage IV Metastatic Colorectal Cancer (mCRC) Subjects
Status: Enrolling
Updated:  2/19/2013
Investigative Clinical Research of Indiana, LLC
mi
from
Indianapolis, IN
A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy
A Phase 2, Open Label, Multicenter, Randomized Trial Comparing Tivozanib in Combination With mFOLFOX6 to Bevacizumab in Combination With mFOLFOX6, In Stage IV Metastatic Colorectal Cancer (mCRC) Subjects
Status: Enrolling
Updated: 2/19/2013
Investigative Clinical Research of Indiana, LLC
mi
from
Indianapolis, IN
Click here to add this to my saved trials
A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy
A Phase 2, Open Label, Multicenter, Randomized Trial Comparing Tivozanib in Combination With mFOLFOX6 to Bevacizumab in Combination With mFOLFOX6, In Stage IV Metastatic Colorectal Cancer (mCRC) Subjects
Status: Enrolling
Updated:  2/19/2013
Horizon Oncology Research, Inc.
mi
from
Lafayette, IN
A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy
A Phase 2, Open Label, Multicenter, Randomized Trial Comparing Tivozanib in Combination With mFOLFOX6 to Bevacizumab in Combination With mFOLFOX6, In Stage IV Metastatic Colorectal Cancer (mCRC) Subjects
Status: Enrolling
Updated: 2/19/2013
Horizon Oncology Research, Inc.
mi
from
Lafayette, IN
Click here to add this to my saved trials
A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy
A Phase 2, Open Label, Multicenter, Randomized Trial Comparing Tivozanib in Combination With mFOLFOX6 to Bevacizumab in Combination With mFOLFOX6, In Stage IV Metastatic Colorectal Cancer (mCRC) Subjects
Status: Enrolling
Updated:  2/19/2013
Lafayette General Medical Center
mi
from
Lafayette, LA
A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy
A Phase 2, Open Label, Multicenter, Randomized Trial Comparing Tivozanib in Combination With mFOLFOX6 to Bevacizumab in Combination With mFOLFOX6, In Stage IV Metastatic Colorectal Cancer (mCRC) Subjects
Status: Enrolling
Updated: 2/19/2013
Lafayette General Medical Center
mi
from
Lafayette, LA
Click here to add this to my saved trials
A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy
A Phase 2, Open Label, Multicenter, Randomized Trial Comparing Tivozanib in Combination With mFOLFOX6 to Bevacizumab in Combination With mFOLFOX6, In Stage IV Metastatic Colorectal Cancer (mCRC) Subjects
Status: Enrolling
Updated:  2/19/2013
Associates in Oncology and Hematology
mi
from
Rockville, MD
A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy
A Phase 2, Open Label, Multicenter, Randomized Trial Comparing Tivozanib in Combination With mFOLFOX6 to Bevacizumab in Combination With mFOLFOX6, In Stage IV Metastatic Colorectal Cancer (mCRC) Subjects
Status: Enrolling
Updated: 2/19/2013
Associates in Oncology and Hematology
mi
from
Rockville, MD
Click here to add this to my saved trials
A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy
A Phase 2, Open Label, Multicenter, Randomized Trial Comparing Tivozanib in Combination With mFOLFOX6 to Bevacizumab in Combination With mFOLFOX6, In Stage IV Metastatic Colorectal Cancer (mCRC) Subjects
Status: Enrolling
Updated:  2/19/2013
University of Michigan Hospital and Health Center
mi
from
Ann Arbor, MI
A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy
A Phase 2, Open Label, Multicenter, Randomized Trial Comparing Tivozanib in Combination With mFOLFOX6 to Bevacizumab in Combination With mFOLFOX6, In Stage IV Metastatic Colorectal Cancer (mCRC) Subjects
Status: Enrolling
Updated: 2/19/2013
University of Michigan Hospital and Health Center
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy
A Phase 2, Open Label, Multicenter, Randomized Trial Comparing Tivozanib in Combination With mFOLFOX6 to Bevacizumab in Combination With mFOLFOX6, In Stage IV Metastatic Colorectal Cancer (mCRC) Subjects
Status: Enrolling
Updated:  2/19/2013
Trinitas Comprehensive Cancer Center
mi
from
Elizabeth, NJ
A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy
A Phase 2, Open Label, Multicenter, Randomized Trial Comparing Tivozanib in Combination With mFOLFOX6 to Bevacizumab in Combination With mFOLFOX6, In Stage IV Metastatic Colorectal Cancer (mCRC) Subjects
Status: Enrolling
Updated: 2/19/2013
Trinitas Comprehensive Cancer Center
mi
from
Elizabeth, NJ
Click here to add this to my saved trials
A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy
A Phase 2, Open Label, Multicenter, Randomized Trial Comparing Tivozanib in Combination With mFOLFOX6 to Bevacizumab in Combination With mFOLFOX6, In Stage IV Metastatic Colorectal Cancer (mCRC) Subjects
Status: Enrolling
Updated:  2/19/2013
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy
A Phase 2, Open Label, Multicenter, Randomized Trial Comparing Tivozanib in Combination With mFOLFOX6 to Bevacizumab in Combination With mFOLFOX6, In Stage IV Metastatic Colorectal Cancer (mCRC) Subjects
Status: Enrolling
Updated: 2/19/2013
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy
A Phase 2, Open Label, Multicenter, Randomized Trial Comparing Tivozanib in Combination With mFOLFOX6 to Bevacizumab in Combination With mFOLFOX6, In Stage IV Metastatic Colorectal Cancer (mCRC) Subjects
Status: Enrolling
Updated:  2/19/2013
NYU Cancer Institute
mi
from
New York, NY
A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy
A Phase 2, Open Label, Multicenter, Randomized Trial Comparing Tivozanib in Combination With mFOLFOX6 to Bevacizumab in Combination With mFOLFOX6, In Stage IV Metastatic Colorectal Cancer (mCRC) Subjects
Status: Enrolling
Updated: 2/19/2013
NYU Cancer Institute
mi
from
New York, NY
Click here to add this to my saved trials
A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy
A Phase 2, Open Label, Multicenter, Randomized Trial Comparing Tivozanib in Combination With mFOLFOX6 to Bevacizumab in Combination With mFOLFOX6, In Stage IV Metastatic Colorectal Cancer (mCRC) Subjects
Status: Enrolling
Updated:  2/19/2013
Alamance Regional Medical Center Cancer Center
mi
from
Burlington, NC
A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy
A Phase 2, Open Label, Multicenter, Randomized Trial Comparing Tivozanib in Combination With mFOLFOX6 to Bevacizumab in Combination With mFOLFOX6, In Stage IV Metastatic Colorectal Cancer (mCRC) Subjects
Status: Enrolling
Updated: 2/19/2013
Alamance Regional Medical Center Cancer Center
mi
from
Burlington, NC
Click here to add this to my saved trials
A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy
A Phase 2, Open Label, Multicenter, Randomized Trial Comparing Tivozanib in Combination With mFOLFOX6 to Bevacizumab in Combination With mFOLFOX6, In Stage IV Metastatic Colorectal Cancer (mCRC) Subjects
Status: Enrolling
Updated:  2/19/2013
Tri Country Hematology / Oncology
mi
from
Canton, OH
A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy
A Phase 2, Open Label, Multicenter, Randomized Trial Comparing Tivozanib in Combination With mFOLFOX6 to Bevacizumab in Combination With mFOLFOX6, In Stage IV Metastatic Colorectal Cancer (mCRC) Subjects
Status: Enrolling
Updated: 2/19/2013
Tri Country Hematology / Oncology
mi
from
Canton, OH
Click here to add this to my saved trials
A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy
A Phase 2, Open Label, Multicenter, Randomized Trial Comparing Tivozanib in Combination With mFOLFOX6 to Bevacizumab in Combination With mFOLFOX6, In Stage IV Metastatic Colorectal Cancer (mCRC) Subjects
Status: Enrolling
Updated:  2/19/2013
Signal Point Clinical Research Center, LLC
mi
from
Middletown, OH
A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy
A Phase 2, Open Label, Multicenter, Randomized Trial Comparing Tivozanib in Combination With mFOLFOX6 to Bevacizumab in Combination With mFOLFOX6, In Stage IV Metastatic Colorectal Cancer (mCRC) Subjects
Status: Enrolling
Updated: 2/19/2013
Signal Point Clinical Research Center, LLC
mi
from
Middletown, OH
Click here to add this to my saved trials
A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy
A Phase 2, Open Label, Multicenter, Randomized Trial Comparing Tivozanib in Combination With mFOLFOX6 to Bevacizumab in Combination With mFOLFOX6, In Stage IV Metastatic Colorectal Cancer (mCRC) Subjects
Status: Enrolling
Updated:  2/19/2013
Cancer Care Associates
mi
from
Oklahoma City, OK
A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy
A Phase 2, Open Label, Multicenter, Randomized Trial Comparing Tivozanib in Combination With mFOLFOX6 to Bevacizumab in Combination With mFOLFOX6, In Stage IV Metastatic Colorectal Cancer (mCRC) Subjects
Status: Enrolling
Updated: 2/19/2013
Cancer Care Associates
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy
A Phase 2, Open Label, Multicenter, Randomized Trial Comparing Tivozanib in Combination With mFOLFOX6 to Bevacizumab in Combination With mFOLFOX6, In Stage IV Metastatic Colorectal Cancer (mCRC) Subjects
Status: Enrolling
Updated:  2/19/2013
Oregon Health and Science University
mi
from
Portland, OR
A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy
A Phase 2, Open Label, Multicenter, Randomized Trial Comparing Tivozanib in Combination With mFOLFOX6 to Bevacizumab in Combination With mFOLFOX6, In Stage IV Metastatic Colorectal Cancer (mCRC) Subjects
Status: Enrolling
Updated: 2/19/2013
Oregon Health and Science University
mi
from
Portland, OR
Click here to add this to my saved trials
A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy
A Phase 2, Open Label, Multicenter, Randomized Trial Comparing Tivozanib in Combination With mFOLFOX6 to Bevacizumab in Combination With mFOLFOX6, In Stage IV Metastatic Colorectal Cancer (mCRC) Subjects
Status: Enrolling
Updated:  2/19/2013
St Luke'S Hospital And Health Network
mi
from
Bethlehem, PA
A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy
A Phase 2, Open Label, Multicenter, Randomized Trial Comparing Tivozanib in Combination With mFOLFOX6 to Bevacizumab in Combination With mFOLFOX6, In Stage IV Metastatic Colorectal Cancer (mCRC) Subjects
Status: Enrolling
Updated: 2/19/2013
St Luke'S Hospital And Health Network
mi
from
Bethlehem, PA
Click here to add this to my saved trials
A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy
A Phase 2, Open Label, Multicenter, Randomized Trial Comparing Tivozanib in Combination With mFOLFOX6 to Bevacizumab in Combination With mFOLFOX6, In Stage IV Metastatic Colorectal Cancer (mCRC) Subjects
Status: Enrolling
Updated:  2/19/2013
Northern Utah Associates
mi
from
Ogden, UT
A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy
A Phase 2, Open Label, Multicenter, Randomized Trial Comparing Tivozanib in Combination With mFOLFOX6 to Bevacizumab in Combination With mFOLFOX6, In Stage IV Metastatic Colorectal Cancer (mCRC) Subjects
Status: Enrolling
Updated: 2/19/2013
Northern Utah Associates
mi
from
Ogden, UT
Click here to add this to my saved trials
A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy
A Phase 2, Open Label, Multicenter, Randomized Trial Comparing Tivozanib in Combination With mFOLFOX6 to Bevacizumab in Combination With mFOLFOX6, In Stage IV Metastatic Colorectal Cancer (mCRC) Subjects
Status: Enrolling
Updated:  2/19/2013
Seattle Cancer Care Alliance
mi
from
Seattle, WA
A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy
A Phase 2, Open Label, Multicenter, Randomized Trial Comparing Tivozanib in Combination With mFOLFOX6 to Bevacizumab in Combination With mFOLFOX6, In Stage IV Metastatic Colorectal Cancer (mCRC) Subjects
Status: Enrolling
Updated: 2/19/2013
Seattle Cancer Care Alliance
mi
from
Seattle, WA
Click here to add this to my saved trials
A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy
A Phase 2, Open Label, Multicenter, Randomized Trial Comparing Tivozanib in Combination With mFOLFOX6 to Bevacizumab in Combination With mFOLFOX6, In Stage IV Metastatic Colorectal Cancer (mCRC) Subjects
Status: Enrolling
Updated:  2/19/2013
Evergreen Hematology & Oncology
mi
from
Spokane, WA
A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy
A Phase 2, Open Label, Multicenter, Randomized Trial Comparing Tivozanib in Combination With mFOLFOX6 to Bevacizumab in Combination With mFOLFOX6, In Stage IV Metastatic Colorectal Cancer (mCRC) Subjects
Status: Enrolling
Updated: 2/19/2013
Evergreen Hematology & Oncology
mi
from
Spokane, WA
Click here to add this to my saved trials
Colorectal Polyp Discrimination Using High-Definition Narrow Band Imaging
Colorectal Polyp Discrimination Using High-Definition Narrow Band Imaging
Status: Enrolling
Updated:  2/25/2013
Mayo Clinic
mi
from
Jacksonville, FL
Colorectal Polyp Discrimination Using High-Definition Narrow Band Imaging
Colorectal Polyp Discrimination Using High-Definition Narrow Band Imaging
Status: Enrolling
Updated: 2/25/2013
Mayo Clinic
mi
from
Jacksonville, FL
Click here to add this to my saved trials
DCE-MRI PET Bevacizumab Study in Rectal Cancer
A Phase II/Pharmacodynamic Study of Preoperative or Definitive FOLFOX Plus Bevacizumab, With the Additional Pharmacodynamic Goal of Assessing Tumor Blood Flow as Measured by Dynamic Contrast-enhanced MRI, and the Induction of Hypoxia and Apoptosis as Measured by PET in Patients With Rectal Cancer
Status: Enrolling
Updated:  2/25/2013
Abramson Cancer Center of the University of Pennsylvania
mi
from
Philadelphia, PA
DCE-MRI PET Bevacizumab Study in Rectal Cancer
A Phase II/Pharmacodynamic Study of Preoperative or Definitive FOLFOX Plus Bevacizumab, With the Additional Pharmacodynamic Goal of Assessing Tumor Blood Flow as Measured by Dynamic Contrast-enhanced MRI, and the Induction of Hypoxia and Apoptosis as Measured by PET in Patients With Rectal Cancer
Status: Enrolling
Updated: 2/25/2013
Abramson Cancer Center of the University of Pennsylvania
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Patients' Opinions and Responses to the National Cancer Institute's Colorectal Cancer Risk Assessment Tool
Patients' Opinions and Responses to the National Cancer Institute's Colorectal Cancer Risk Assessment Tool
Status: Enrolling
Updated:  3/1/2013
Indiana University Health
mi
from
Indianapolis, IN
Patients' Opinions and Responses to the National Cancer Institute's Colorectal Cancer Risk Assessment Tool
Patients' Opinions and Responses to the National Cancer Institute's Colorectal Cancer Risk Assessment Tool
Status: Enrolling
Updated: 3/1/2013
Indiana University Health
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Study of Biomarkers in Blood & Tissue Samples From Patients With Colorectal Cancer or Polyps & Patients Without Polyps
Cancer Care Engineering of Colorectal Cancer - OMICs Pilot Study
Status: Enrolling
Updated:  3/6/2013
Indiana University Melvin and Bren Simon Cancer Center
mi
from
Indianapolis, IN
Study of Biomarkers in Blood & Tissue Samples From Patients With Colorectal Cancer or Polyps & Patients Without Polyps
Cancer Care Engineering of Colorectal Cancer - OMICs Pilot Study
Status: Enrolling
Updated: 3/6/2013
Indiana University Melvin and Bren Simon Cancer Center
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Effect of Sorafenib or Regorafenib on P63 Expression and Keratinocyte Differentiation in Human Skin
A Study of the Effect of Sorafenib or Regorafenib on p63 Expression and Keratinocyte Differentiation in Human Skin
Status: Enrolling
Updated:  3/8/2013
Dartmouth Hitchcock Medical Center/Norris Cotton Cancer Center
mi
from
Lebanon, NH
Effect of Sorafenib or Regorafenib on P63 Expression and Keratinocyte Differentiation in Human Skin
A Study of the Effect of Sorafenib or Regorafenib on p63 Expression and Keratinocyte Differentiation in Human Skin
Status: Enrolling
Updated: 3/8/2013
Dartmouth Hitchcock Medical Center/Norris Cotton Cancer Center
mi
from
Lebanon, NH
Click here to add this to my saved trials
Effect of Sorafenib or Regorafenib on P63 Expression and Keratinocyte Differentiation in Human Skin
A Study of the Effect of Sorafenib or Regorafenib on p63 Expression and Keratinocyte Differentiation in Human Skin
Status: Enrolling
Updated:  3/8/2013
White River Junction VA Medical Center
mi
from
White River Junction, VT
Effect of Sorafenib or Regorafenib on P63 Expression and Keratinocyte Differentiation in Human Skin
A Study of the Effect of Sorafenib or Regorafenib on p63 Expression and Keratinocyte Differentiation in Human Skin
Status: Enrolling
Updated: 3/8/2013
White River Junction VA Medical Center
mi
from
White River Junction, VT
Click here to add this to my saved trials
Community-based Approaches to Treating Hypertension and Colon Cancer Prevention
Community-based Approaches to Treating Hypertension and Colon Cancer Prevention
Status: Enrolling
Updated:  3/12/2013
NYU School of Medicine
mi
from
New York, NY
Community-based Approaches to Treating Hypertension and Colon Cancer Prevention
Community-based Approaches to Treating Hypertension and Colon Cancer Prevention
Status: Enrolling
Updated: 3/12/2013
NYU School of Medicine
mi
from
New York, NY
Click here to add this to my saved trials
Active Immunotherapy CEA Vaccine in Patients With Malignancies Expressing CEA
A Phase I/II Study of Active Immunotherapy With Ad5[E1-,E2b-]-CEA Vaccine in Patients With Advanced or Metastatic Malignancies Expressing CEA
Status: Enrolling
Updated:  3/21/2013
Duke Cancer Research Institute, Duke University
mi
from
Durham, NC
Active Immunotherapy CEA Vaccine in Patients With Malignancies Expressing CEA
A Phase I/II Study of Active Immunotherapy With Ad5[E1-,E2b-]-CEA Vaccine in Patients With Advanced or Metastatic Malignancies Expressing CEA
Status: Enrolling
Updated: 3/21/2013
Duke Cancer Research Institute, Duke University
mi
from
Durham, NC
Click here to add this to my saved trials
Active Immunotherapy CEA Vaccine in Patients With Malignancies Expressing CEA
A Phase I/II Study of Active Immunotherapy With Ad5[E1-,E2b-]-CEA Vaccine in Patients With Advanced or Metastatic Malignancies Expressing CEA
Status: Enrolling
Updated:  3/21/2013
Medical Oncology Associates PS
mi
from
Spokane, WA
Active Immunotherapy CEA Vaccine in Patients With Malignancies Expressing CEA
A Phase I/II Study of Active Immunotherapy With Ad5[E1-,E2b-]-CEA Vaccine in Patients With Advanced or Metastatic Malignancies Expressing CEA
Status: Enrolling
Updated: 3/21/2013
Medical Oncology Associates PS
mi
from
Spokane, WA
Click here to add this to my saved trials
A Trial of Dalotuzumab in Combination With Irinotecan Versus Cetuximab and Irinotecan for Participants With Metastatic Rectal Cancers (mRC) (MK-0646-025 AM4)
A Phase IIA Open Label, Adaptive, Randomized Clinical Trial of Dalotuzumab (MK-0646) Treatment in Combination With Irinotecan Versus Cetuximab and Irinotecan for Patients With Metastatic Rectal Cancers (mRC) Expressing High IGF-1/Low IGF-2 Levels
Status: Enrolling
Updated:  3/22/2013
Clinical Research Facility
mi
from
Wichita, KA
A Trial of Dalotuzumab in Combination With Irinotecan Versus Cetuximab and Irinotecan for Participants With Metastatic Rectal Cancers (mRC) (MK-0646-025 AM4)
A Phase IIA Open Label, Adaptive, Randomized Clinical Trial of Dalotuzumab (MK-0646) Treatment in Combination With Irinotecan Versus Cetuximab and Irinotecan for Patients With Metastatic Rectal Cancers (mRC) Expressing High IGF-1/Low IGF-2 Levels
Status: Enrolling
Updated: 3/22/2013
Clinical Research Facility
mi
from
Wichita, KA
Click here to add this to my saved trials
A Trial of Dalotuzumab in Combination With Irinotecan Versus Cetuximab and Irinotecan for Participants With Metastatic Rectal Cancers (mRC) (MK-0646-025 AM4)
A Phase IIA Open Label, Adaptive, Randomized Clinical Trial of Dalotuzumab (MK-0646) Treatment in Combination With Irinotecan Versus Cetuximab and Irinotecan for Patients With Metastatic Rectal Cancers (mRC) Expressing High IGF-1/Low IGF-2 Levels
Status: Enrolling
Updated:  3/22/2013
Clinical Research Facility
mi
from
New Brunswick, NJ
A Trial of Dalotuzumab in Combination With Irinotecan Versus Cetuximab and Irinotecan for Participants With Metastatic Rectal Cancers (mRC) (MK-0646-025 AM4)
A Phase IIA Open Label, Adaptive, Randomized Clinical Trial of Dalotuzumab (MK-0646) Treatment in Combination With Irinotecan Versus Cetuximab and Irinotecan for Patients With Metastatic Rectal Cancers (mRC) Expressing High IGF-1/Low IGF-2 Levels
Status: Enrolling
Updated: 3/22/2013
Clinical Research Facility
mi
from
New Brunswick, NJ
Click here to add this to my saved trials
A Trial of Dalotuzumab in Combination With Irinotecan Versus Cetuximab and Irinotecan for Participants With Metastatic Rectal Cancers (mRC) (MK-0646-025 AM4)
A Phase IIA Open Label, Adaptive, Randomized Clinical Trial of Dalotuzumab (MK-0646) Treatment in Combination With Irinotecan Versus Cetuximab and Irinotecan for Patients With Metastatic Rectal Cancers (mRC) Expressing High IGF-1/Low IGF-2 Levels
Status: Enrolling
Updated:  3/22/2013
Clinical Research Facility
mi
from
Greensboro, NC
A Trial of Dalotuzumab in Combination With Irinotecan Versus Cetuximab and Irinotecan for Participants With Metastatic Rectal Cancers (mRC) (MK-0646-025 AM4)
A Phase IIA Open Label, Adaptive, Randomized Clinical Trial of Dalotuzumab (MK-0646) Treatment in Combination With Irinotecan Versus Cetuximab and Irinotecan for Patients With Metastatic Rectal Cancers (mRC) Expressing High IGF-1/Low IGF-2 Levels
Status: Enrolling
Updated: 3/22/2013
Clinical Research Facility
mi
from
Greensboro, NC
Click here to add this to my saved trials
A Trial of Dalotuzumab in Combination With Irinotecan Versus Cetuximab and Irinotecan for Participants With Metastatic Rectal Cancers (mRC) (MK-0646-025 AM4)
A Phase IIA Open Label, Adaptive, Randomized Clinical Trial of Dalotuzumab (MK-0646) Treatment in Combination With Irinotecan Versus Cetuximab and Irinotecan for Patients With Metastatic Rectal Cancers (mRC) Expressing High IGF-1/Low IGF-2 Levels
Status: Enrolling
Updated:  3/22/2013
Clinical Research Facility
mi
from
Nashville, TN
A Trial of Dalotuzumab in Combination With Irinotecan Versus Cetuximab and Irinotecan for Participants With Metastatic Rectal Cancers (mRC) (MK-0646-025 AM4)
A Phase IIA Open Label, Adaptive, Randomized Clinical Trial of Dalotuzumab (MK-0646) Treatment in Combination With Irinotecan Versus Cetuximab and Irinotecan for Patients With Metastatic Rectal Cancers (mRC) Expressing High IGF-1/Low IGF-2 Levels
Status: Enrolling
Updated: 3/22/2013
Clinical Research Facility
mi
from
Nashville, TN
Click here to add this to my saved trials
Colon Cancer Study of Fecal Samples in Shanghai, China
Pilot Study of the Fecal Microbiome in the Shanghai Population
Status: Enrolling
Updated:  4/5/2013
National Cancer Institute , 9000 Rockville Pike
mi
from
Bethesda, MD
Colon Cancer Study of Fecal Samples in Shanghai, China
Pilot Study of the Fecal Microbiome in the Shanghai Population
Status: Enrolling
Updated: 4/5/2013
National Cancer Institute , 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Drug-Eluting Bead, Irinotecan (DEBIRI) Therapy of Liver Metastasis From Colon Cancer With Systemic FOLFOX6
Drug-Eluting Bead, Irinotecan (DEBIRI) Therapy of Liver Metastasis From Colon Cancer With Concomitant Systemic Oxaliplatin, Fluorouracil and Leucovorin Chemotherapy, and Anti-Angiogenic Therapy
Status: Enrolling
Updated:  4/17/2013
Clearview Cancer Center
mi
from
Huntsville, AL
Drug-Eluting Bead, Irinotecan (DEBIRI) Therapy of Liver Metastasis From Colon Cancer With Systemic FOLFOX6
Drug-Eluting Bead, Irinotecan (DEBIRI) Therapy of Liver Metastasis From Colon Cancer With Concomitant Systemic Oxaliplatin, Fluorouracil and Leucovorin Chemotherapy, and Anti-Angiogenic Therapy
Status: Enrolling
Updated: 4/17/2013
Clearview Cancer Center
mi
from
Huntsville, AL
Click here to add this to my saved trials
Drug-Eluting Bead, Irinotecan (DEBIRI) Therapy of Liver Metastasis From Colon Cancer With Systemic FOLFOX6
Drug-Eluting Bead, Irinotecan (DEBIRI) Therapy of Liver Metastasis From Colon Cancer With Concomitant Systemic Oxaliplatin, Fluorouracil and Leucovorin Chemotherapy, and Anti-Angiogenic Therapy
Status: Enrolling
Updated:  4/17/2013
Radiology Associates of Sacramento/Sutter Cancer Center
mi
from
Sacramento, CA
Drug-Eluting Bead, Irinotecan (DEBIRI) Therapy of Liver Metastasis From Colon Cancer With Systemic FOLFOX6
Drug-Eluting Bead, Irinotecan (DEBIRI) Therapy of Liver Metastasis From Colon Cancer With Concomitant Systemic Oxaliplatin, Fluorouracil and Leucovorin Chemotherapy, and Anti-Angiogenic Therapy
Status: Enrolling
Updated: 4/17/2013
Radiology Associates of Sacramento/Sutter Cancer Center
mi
from
Sacramento, CA
Click here to add this to my saved trials
Drug-Eluting Bead, Irinotecan (DEBIRI) Therapy of Liver Metastasis From Colon Cancer With Systemic FOLFOX6
Drug-Eluting Bead, Irinotecan (DEBIRI) Therapy of Liver Metastasis From Colon Cancer With Concomitant Systemic Oxaliplatin, Fluorouracil and Leucovorin Chemotherapy, and Anti-Angiogenic Therapy
Status: Enrolling
Updated:  4/17/2013
Emory University
mi
from
Atlanta, GA
Drug-Eluting Bead, Irinotecan (DEBIRI) Therapy of Liver Metastasis From Colon Cancer With Systemic FOLFOX6
Drug-Eluting Bead, Irinotecan (DEBIRI) Therapy of Liver Metastasis From Colon Cancer With Concomitant Systemic Oxaliplatin, Fluorouracil and Leucovorin Chemotherapy, and Anti-Angiogenic Therapy
Status: Enrolling
Updated: 4/17/2013
Emory University
mi
from
Atlanta, GA
Click here to add this to my saved trials
Drug-Eluting Bead, Irinotecan (DEBIRI) Therapy of Liver Metastasis From Colon Cancer With Systemic FOLFOX6
Drug-Eluting Bead, Irinotecan (DEBIRI) Therapy of Liver Metastasis From Colon Cancer With Concomitant Systemic Oxaliplatin, Fluorouracil and Leucovorin Chemotherapy, and Anti-Angiogenic Therapy
Status: Enrolling
Updated:  4/17/2013
Northside Hospital/GA Cancer Specialists
mi
from
Atlanta, GA
Drug-Eluting Bead, Irinotecan (DEBIRI) Therapy of Liver Metastasis From Colon Cancer With Systemic FOLFOX6
Drug-Eluting Bead, Irinotecan (DEBIRI) Therapy of Liver Metastasis From Colon Cancer With Concomitant Systemic Oxaliplatin, Fluorouracil and Leucovorin Chemotherapy, and Anti-Angiogenic Therapy
Status: Enrolling
Updated: 4/17/2013
Northside Hospital/GA Cancer Specialists
mi
from
Atlanta, GA
Click here to add this to my saved trials
Drug-Eluting Bead, Irinotecan (DEBIRI) Therapy of Liver Metastasis From Colon Cancer With Systemic FOLFOX6
Drug-Eluting Bead, Irinotecan (DEBIRI) Therapy of Liver Metastasis From Colon Cancer With Concomitant Systemic Oxaliplatin, Fluorouracil and Leucovorin Chemotherapy, and Anti-Angiogenic Therapy
Status: Enrolling
Updated:  4/17/2013
University of Louisville
mi
from
Louisville, KY
Drug-Eluting Bead, Irinotecan (DEBIRI) Therapy of Liver Metastasis From Colon Cancer With Systemic FOLFOX6
Drug-Eluting Bead, Irinotecan (DEBIRI) Therapy of Liver Metastasis From Colon Cancer With Concomitant Systemic Oxaliplatin, Fluorouracil and Leucovorin Chemotherapy, and Anti-Angiogenic Therapy
Status: Enrolling
Updated: 4/17/2013
University of Louisville
mi
from
Louisville, KY
Click here to add this to my saved trials
Drug-Eluting Bead, Irinotecan (DEBIRI) Therapy of Liver Metastasis From Colon Cancer With Systemic FOLFOX6
Drug-Eluting Bead, Irinotecan (DEBIRI) Therapy of Liver Metastasis From Colon Cancer With Concomitant Systemic Oxaliplatin, Fluorouracil and Leucovorin Chemotherapy, and Anti-Angiogenic Therapy
Status: Enrolling
Updated:  4/17/2013
Hematology and Oncology Assoc. at Bridgeport
mi
from
Tupelo, MS
Drug-Eluting Bead, Irinotecan (DEBIRI) Therapy of Liver Metastasis From Colon Cancer With Systemic FOLFOX6
Drug-Eluting Bead, Irinotecan (DEBIRI) Therapy of Liver Metastasis From Colon Cancer With Concomitant Systemic Oxaliplatin, Fluorouracil and Leucovorin Chemotherapy, and Anti-Angiogenic Therapy
Status: Enrolling
Updated: 4/17/2013
Hematology and Oncology Assoc. at Bridgeport
mi
from
Tupelo, MS
Click here to add this to my saved trials
Drug-Eluting Bead, Irinotecan (DEBIRI) Therapy of Liver Metastasis From Colon Cancer With Systemic FOLFOX6
Drug-Eluting Bead, Irinotecan (DEBIRI) Therapy of Liver Metastasis From Colon Cancer With Concomitant Systemic Oxaliplatin, Fluorouracil and Leucovorin Chemotherapy, and Anti-Angiogenic Therapy
Status: Enrolling
Updated:  4/17/2013
Washington University/Alvin J. Siteman Cancer Center
mi
from
St. Louis, MO
Drug-Eluting Bead, Irinotecan (DEBIRI) Therapy of Liver Metastasis From Colon Cancer With Systemic FOLFOX6
Drug-Eluting Bead, Irinotecan (DEBIRI) Therapy of Liver Metastasis From Colon Cancer With Concomitant Systemic Oxaliplatin, Fluorouracil and Leucovorin Chemotherapy, and Anti-Angiogenic Therapy
Status: Enrolling
Updated: 4/17/2013
Washington University/Alvin J. Siteman Cancer Center
mi
from
St. Louis, MO
Click here to add this to my saved trials
Drug-Eluting Bead, Irinotecan (DEBIRI) Therapy of Liver Metastasis From Colon Cancer With Systemic FOLFOX6
Drug-Eluting Bead, Irinotecan (DEBIRI) Therapy of Liver Metastasis From Colon Cancer With Concomitant Systemic Oxaliplatin, Fluorouracil and Leucovorin Chemotherapy, and Anti-Angiogenic Therapy
Status: Enrolling
Updated:  4/17/2013
Providence Portland Medical Center/Providence Cancer Center
mi
from
Portland, OR
Drug-Eluting Bead, Irinotecan (DEBIRI) Therapy of Liver Metastasis From Colon Cancer With Systemic FOLFOX6
Drug-Eluting Bead, Irinotecan (DEBIRI) Therapy of Liver Metastasis From Colon Cancer With Concomitant Systemic Oxaliplatin, Fluorouracil and Leucovorin Chemotherapy, and Anti-Angiogenic Therapy
Status: Enrolling
Updated: 4/17/2013
Providence Portland Medical Center/Providence Cancer Center
mi
from
Portland, OR
Click here to add this to my saved trials
Drug-Eluting Bead, Irinotecan (DEBIRI) Therapy of Liver Metastasis From Colon Cancer With Systemic FOLFOX6
Drug-Eluting Bead, Irinotecan (DEBIRI) Therapy of Liver Metastasis From Colon Cancer With Concomitant Systemic Oxaliplatin, Fluorouracil and Leucovorin Chemotherapy, and Anti-Angiogenic Therapy
Status: Enrolling
Updated:  4/17/2013
Froedtert Memorial Lutheran Hospital
mi
from
Milwaukee, WI
Drug-Eluting Bead, Irinotecan (DEBIRI) Therapy of Liver Metastasis From Colon Cancer With Systemic FOLFOX6
Drug-Eluting Bead, Irinotecan (DEBIRI) Therapy of Liver Metastasis From Colon Cancer With Concomitant Systemic Oxaliplatin, Fluorouracil and Leucovorin Chemotherapy, and Anti-Angiogenic Therapy
Status: Enrolling
Updated: 4/17/2013
Froedtert Memorial Lutheran Hospital
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Drug-Eluting Bead, Irinotecan (DEBIRI) Therapy of Liver Metastasis From Colon Cancer With Systemic FOLFOX6
Drug-Eluting Bead, Irinotecan (DEBIRI) Therapy of Liver Metastasis From Colon Cancer With Concomitant Systemic Oxaliplatin, Fluorouracil and Leucovorin Chemotherapy, and Anti-Angiogenic Therapy
Status: Enrolling
Updated:  4/17/2013
Hospital Italiano de Buenos Aires
mi
from
Buenos Aires,
Drug-Eluting Bead, Irinotecan (DEBIRI) Therapy of Liver Metastasis From Colon Cancer With Systemic FOLFOX6
Drug-Eluting Bead, Irinotecan (DEBIRI) Therapy of Liver Metastasis From Colon Cancer With Concomitant Systemic Oxaliplatin, Fluorouracil and Leucovorin Chemotherapy, and Anti-Angiogenic Therapy
Status: Enrolling
Updated: 4/17/2013
Hospital Italiano de Buenos Aires
mi
from
Buenos Aires,
Click here to add this to my saved trials
Extralevator Versus Standard Abdominoperineal Resection For Rectal Adenocarcinoma
Multicenter Randomized Controlled Trial, Extralevator Versus Standard Abdominoperineal Resection For Rectal Adenocarcinoma
Status: Enrolling
Updated:  4/23/2013
State University Hospital Medical Center
mi
from
Stony Brook, NY
Extralevator Versus Standard Abdominoperineal Resection For Rectal Adenocarcinoma
Multicenter Randomized Controlled Trial, Extralevator Versus Standard Abdominoperineal Resection For Rectal Adenocarcinoma
Status: Enrolling
Updated: 4/23/2013
State University Hospital Medical Center
mi
from
Stony Brook, NY
Click here to add this to my saved trials
Extralevator Versus Standard Abdominoperineal Resection For Rectal Adenocarcinoma
Multicenter Randomized Controlled Trial, Extralevator Versus Standard Abdominoperineal Resection For Rectal Adenocarcinoma
Status: Enrolling
Updated:  4/23/2013
Stony Broook University Medical Center
mi
from
Stony Brook, NY
Extralevator Versus Standard Abdominoperineal Resection For Rectal Adenocarcinoma
Multicenter Randomized Controlled Trial, Extralevator Versus Standard Abdominoperineal Resection For Rectal Adenocarcinoma
Status: Enrolling
Updated: 4/23/2013
Stony Broook University Medical Center
mi
from
Stony Brook, NY
Click here to add this to my saved trials
Extralevator Versus Standard Abdominoperineal Resection For Rectal Adenocarcinoma
Multicenter Randomized Controlled Trial, Extralevator Versus Standard Abdominoperineal Resection For Rectal Adenocarcinoma
Status: Enrolling
Updated:  4/23/2013
Stony Brook University Medical Center
mi
from
Stony Brook, NY
Extralevator Versus Standard Abdominoperineal Resection For Rectal Adenocarcinoma
Multicenter Randomized Controlled Trial, Extralevator Versus Standard Abdominoperineal Resection For Rectal Adenocarcinoma
Status: Enrolling
Updated: 4/23/2013
Stony Brook University Medical Center
mi
from
Stony Brook, NY
Click here to add this to my saved trials